Austar Lifesciences Limited provided earnings guidance for the six months ended 30 June 2021. The Group is expected to record a profit attributable to the owners of the Company of not less than RMB 200 million for the six months ended 30 June 2021, as compared to the profit attributable to the owners of the Company of approximately RMB 12.8 million for the six months ended 30 June 2020.